1. A method for producing a stable boron solution with lubricating characteristics which is intended to be used preferably as an addition in the form of a concentrateadditive to a liquid, e.g. to a liquid fuel or a lubricant,
the method comprising the steps of
using a boron substance of pharmaceutical quality,
using a liquid as solvent,
applying a mixing ratio between the boron substance and the solvent of preferably 1 g of boron per 15-25 litres of liquid,
agitating the mixture for an initial predetermined period of time,
adding further liquid to dilute the solution, the quantity of liquid being chosen such that a final user mixture reaches a concentration of between 20 and 30 ppm of boron, and
further agitating the mixture for a second predetermined period of time so that the boron substance is completely dissolved in the boron solution,
resulting in a boron solution which is stable over time.
2. A method according to claim 1, comprising the further step of
agitating the solution so that its temperature rises but does not reach the breakdown temperature of the liquid.
3. A method according to claim 1, comprising the further step of
using a solvent from among the category of organic liquids.
4. A method according to claim 1, comprising the further step of
using a solvent from among the category of inorganic liquids.
5. A method according to claim 1, comprising the further step of
using a boron substance in powder form.
6. A method according to claim 1, comprising the further step of
using a boron substance in the form of Borax H3BO3.
7. A method according to claim 1, comprising the further step of
using a boron substance in the form of boron oxide B2O3.
8. A method according to claim 1, comprising the further step of
using a boron substance with a purity of at least 99%.
9. A method according to claim 1, comprising the further step of
using a solvent from among the category of kerosene, naphtha, water, vegetablesyntheticfossil oils, alcohol, methane, hydrogen.
10. A method according to claim 1, comprising the further step of
the agitation being by means of a mechanical mixer.
11. A method according to claim 1, comprising the further step of
the agitation being by tumbling.
12. A boron solution with lubricating characteristics, primarily intended as an addition in the form of a concentrateadditive to a liquid, e.g. a liquid fuel or to a lubricant, made by a method according to claim 1.
13. A concentrateadditive to a liquid, comprising a boron solution with lubricating characteristics made by a method according to claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An effect predicting apparatus for predicting an effect of anthracycline anticancer drugs, comprising:
a display,
a processor, and
a memory, under control of said processor, including software instructions adapted to enable the processor to perform operations, comprising:
acquiring a CDK parameter based on a first cyclin dependent kinase (first CDK) parameter and a second cyclin dependent kinase (second CDK) parameter, wherein the first CDK parameter is capable to be acquired from an activity value and an expression level of the first CDK, and the second CDK parameter is capable to be acquired from an activity value and an expression level of the second CDK, contained in a malignant tumor of a patient;
acquiring an expression level of glutathione contained in a malignant tumor of the patient;
comparing the CDK parameter with a CDK threshold value for a CDK parameter, and the expression level of glutathione with a glutathione threshold value for an expression level of glutathione;
predicting an effect of anthracycline anticancer drugs for the patient based on the result of the comparison; and displaying the result of the prediction.
2. The apparatus of claim 1, wherein the operations comprise:
in cancer patients who after excision of malignant tumors, were administered with anthracycline anticancer drugs, comparing a CDK parameters and a expression levels of glutathione in the malignant tumors excised from the cancer patients, with information on recurrence in the cancer patients after excision of the malignant tumors, thereby memorizing threshold values capable of dividing the cancer patients into at least 2 groups different in a risk of recurrence.
3. The apparatus of claim 1, wherein the first parameter is a first CDK specific activity.
4. The apparatus of claim 1, wherein the second parameter is a second CDK specific activity.
5. The apparatus of claim 1, wherein the CDK parameter is a ratio between the first parameter and the second parameter.
6. The apparatus of claim 1, wherein the operations comprise:
a first comparison step of comparing the CDK parameter with a first threshold value and a second comparison step of comparing the expression level of glutathione with a second threshold value.
7. The apparatus of claim 6, wherein the operations comprise:
judging the subject to be anthracycline-susceptible when the CDK parameter is higher the first threshold value and the expression level of glutathione is lower than the second threshold value, as a result of the first and second comparison steps.
8. A computer program product, comprising:
a computer readable medium; and
instructions, on the computer readable medium, adapted to enable a general purpose computer to perform operations, comprising:
acquiring a CDK parameter based on a first cyclin dependent kinase (first CDK) parameter and a second cyclin dependent kinase (second CDK) parameter, wherein the first CDK parameter is capable to be acquired from an activity value and an expression level of the first CDK, and the second CDK parameter is capable to be acquired from an activity value and an expression level of the second CDK, contained in a malignant tumor of a patient;
acquiring an expression level of glutathione contained in a malignant tumor of the patient;
comparing the CDK parameter with a CDK threshold value for a CDK parameter, and the expression level of glutathione with a glutathione threshold value for an expression level of glutathione;
predicting an effect of anthracycline anticancer drugs for the patient based on the result of the comparison; and
displaying the result of the prediction.
9. The computer program product of claim 8, further comprising:
in cancer patients who after excision of malignant tumors, were administered with anthracycline anticancer drugs, comparing a CDK parameters and a expression levels of glutathione in the malignant tumors excised from the cancer patients, with information on recurrence in the cancer patients after excision of the malignant tumors, thereby memorizing threshold values capable of dividing the cancer patients into at least 2 groups different in a risk of recurrence.
10. The computer program product of claim 8, wherein the first parameter is a first CDK specific activity.
11. The computer program product of claim 8, wherein the second parameter is a second CDK specific activity.
12. The computer program product of claim 8, wherein the CDK parameter is a ratio between the first parameter and the second parameter.
13. The computer program product of claim 8, further comprising:
a first comparison step of comparing the CDK parameter with a first threshold value and a second comparison step of comparing the expression level of glutathione with a second threshold value.
14. The computer program product of claim 13, wherein the judging the subject to be anthracycline-susceptible when the CDK parameter is higher the first threshold value and the expression level of glutathione is lower than the second threshold value, as a result of the first and second comparison steps.
15. A method for predicting an effect of anthracycline anticancer drugs comprising:
acquiring a CDK parameter based on a first cyclin dependent kinase (first CDK) parameter and a second cyclin dependent kinase (second CDK) parameter, wherein the first CDK parameter is capable to be acquired from an activity value and an expression level of the first CDK, and the second CDK parameter is capable to be acquired from an activity value and an expression level of the second CDK, contained in a malignant tumor of a patient;
acquiring an expression level of glutathione contained in a malignant tumor of the patient; and
predicting an effect of anthracycline anticancer drugs based on the CDK parameter and the expression level of glutathione.
16. The method of claim 15, wherein the first parameter is a first CDK specific activity.
17. The method of claim 15, wherein the second parameter is a second CDK specific activity.
18. The method of claim 15, wherein the CDK parameter is a ratio between the first parameter and the second parameter.
19. The method of claim 15, further comprising
a first comparison step of comparing the CDK parameter with a first threshold value and a second comparison step of comparing the expression level of glutathione with a second threshold value.
20. The method of claim 19, wherein the judgment step is carried out by judging the subject to be anthracycline-susceptible when the CDK parameter is higher the first threshold value and the expression level of glutathione is lower than the second threshold value, as a result of the first and second comparison steps.